AI Summary
✦ ClarthaZydus Wellness is a consumer-staples company selling health, nutrition, personal-care and household products. Glucon-D and Sugar Free drive functional nutrition, while Complan, Nutralite, Everyuth, Nycil and RiteBite extend its branded portfolio. Revenue grew 46.4% year-on-year, but Q1 profit fell 7% to ₹118.9 crore, indicating growth has not fully converted into earnings. Improving margins provide a positive operating signal, yet profit growth declined 43.2% in the reported period. Debt-to-equity of 54.97 implies leverage can amplify ROE, although ROE is unavailable. At 90 times earnings, the stock is overvalued and trades at a substantial premium to growth. Positive sentiment may support momentum, but earnings conversion and leverage remain key risks.
Price Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 7 analysts
Fundamentals
Fundamentals institutional score is 50 using growth durability 49.5.
Valuation
Valuation institutional score is 34 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 75 using mean target upside 17.5%; dispersion penalty 7.6; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 60 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 3 recent ticker-linked news items.
Signal Summary
Market intelligence remains Mixed. analyst consensus provide support, while fundamentals and valuation remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 33.1% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +1.69). Confidence: 82%.
Live forward EPS implies next-12-month EPS of ₹15.96. Applying the stock's normalized valuation corridor produces a fair range of ₹892.16 to ₹1,191.41, with base value near ₹1,043.94 (+102.3% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹15.96
Forward P/E
32.3x
Base Fair Value
₹1,043.94
Fair Range
₹892.16 - ₹1,191.41
Upside To Base
+102.3%
Estimate Source
Live forward EPS
Growth Estimate
-7.0%
5Y Average
62.64
Current
87.03
Overvalued
74.65
Undervalued
55.90
5Y Average
24.75
Current
34.39
Overvalued
26.99
Undervalued
20.74
5Y Average
2.60
Current
3.62
Overvalued
3.00
Undervalued
2.21
Peers & Comparison
Sector: Consumer Staples · Theme: FMCG - Foods
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
BIKAJI FOODS INTERN LTD BIKAJIFMCG - Foods | +12.5% | 8.4% | 60.6x Premium | +26% vs avg | -13.6% |
HATSUN AGRO PRODUCT LTD. HATSUNFMCG - Foods | +19.3% | 3.4% | 59.9x Premium | +25% vs avg | +5.9% |
VISHAL MEGA MART LIMITED VMMFMCG - Foods | +18.7% | 6.6% | 57.2x Premium | +19% vs avg | -23.4% |
MRS BECTORS FOOD SPE LTD BECTORFOODFMCG - Foods | +16.0% | 7.0% | 50.7x Fair | +6% vs avg | -20.7% |
HINDUSTAN FOODS LIMITED HNDFDSFMCG - Foods | +20.7% | 3.6% | 47.5x Fair | -1% vs avg | +11.1% |
VADILAL INDUSTRIES LTD VADILALINDFMCG - Foods | +57.0% | 10.3% | 34.2x Undervalued | -29% vs avg | +43.0% |
KWALITY WALL'S (INDIA) L KWILFMCG - Foods | +6.3% | -19.5% | — | — | +18.5% |
DODLA DAIRY LIMITED DODLAFMCG - Foods | +19.0% | 5.7% | 25.9x Undervalued | -46% vs avg | -20.6% |
ZYDUS WELLNESS LIMITED trades at a premium (87.0x vs peer avg 48.0x), implying higher growth or quality expectations from the Fmcg - Foods cohort. Peers include BIKAJI FOODS INTERN LTD, HATSUN AGRO PRODUCT LTD., VISHAL MEGA MART LIMITED — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹153 CrDec 2025Latest net profit
₹12 CrDec 2025Latest EPS
₹0.38Dec 2025Net margin
9.1%Dec 2025Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Dec 2025
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 58.8 | 60.1 | 57.8 | 63.8 | 63.1 | 63.4 | 63.3 | 88.4 | 77.5 | 141 | 156 | 153 |
| Expenses | 50.8 | 52.9 | 50.4 | 53 | 55.7 | 58.1 | 55.8 | 74 | 68.5 | 126 | 129 | 132 |
| Operating Profit | 7 | 6.3 | 6.5 | 9.9 | 6.5 | 4.4 | 6.6 | 13.4 | 8.1 | 9.4 | 20.5 | 13.9 |
| OPM % | 11.9% | 10.48% | 11.25% | 15.52% | 10.3% | 6.94% | 10.43% | 15.16% | 10.45% | 6.67% | 13.14% | 9.11% |
| Other Income | 3.6 | 4.1 | 4.7 | 4.6 | 4.8 | 4.8 | 4.1 | 3.6 | 0.3 | 0.8 | 3.2 | 4.9 |
| Interest | 0.1 | — | 0.8 | 0.9 | 0.9 | 0.8 | 0.2 | 1.4 | 2.2 | 2.3 | 2.5 | 3.1 |
| Depreciation | 1 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 1 | 0.9 | 6 | 6.4 | 6.3 |
| Profit before tax | 10.5 | 10.4 | 10.4 | 13.6 | 10.4 | 8.4 | 10.5 | 15.6 | 6.2 | 7.9 | 21.2 | 15.7 |
| Tax % | -173.33% | 23.08% | 25% | 24.26% | 28.85% | 26.19% | 23.81% | 25% | 25.81% | 41.77% | 18.4% | 26.11% |
| Net Profit | 28.7 | 8 | 7.8 | 10.3 | 7.4 | 6.2 | 8 | 11.7 | 4.6 | 4.6 | 17.3 | 11.6 |
| EPS in Rs | 4.50 | 1.29 | 1.23 | 1.62 | 1.16 | 0.97 | 0.25 | 1.84 | 0.74 | 0.14 | 0.24 | 0.38 |
All values in Rs. Crore unless otherwise stated. Source: CMIE Prowess, Quarterly Interim Standalone.